Clinical Therapeutics/New Technology-Insulins

Clinical Therapeutics/New Technology-Insulins

You have access
Glycemic Outcome Associated With Insulin Pump and Glucose Sensor Use in Children and Adolescents With Type 1 Diabetes. Data From the International Pediatric Registry SWEET
Roque Cardona-Hernandez, Anke Schwandt, Hessa Alkandari, Heiko Bratke, Agata Chobot, Nicole Coles, Sarah Corathers, Damla Goksen, Peter Goss, Zineb Imane, Katrin Nagl, Stephen M.P. O’Riordan, Craig Jefferies, for the SWEET Study Group

Diabetes Care Mar 2021, dc201674; DOI: 10.2337/dc20-1674
Open Access
Durable Effects of iGlarLixi Up to 52 Weeks in Type 2 Diabetes: The LixiLan-G Extension Study
Lawrence Blonde, Julio Rosenstock, Juan Frias, Andreas L. Birkenfeld, Elisabeth Niemoeller, Elisabeth Souhami, Chen Ji, Stefano Del Prato, Vanita R. Aroda

Diabetes Care Mar 2021, 44 (3) 774-780; DOI: 10.2337/dc20-2023
Open Access
Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes
Eva Svehlikova, Ines Mursic, Thomas Augustin, Christoph Magnes, David Gerring, Jan Jezek, Daniela Schwarzenbacher, Maria Ratzer, Michael Wolf, Sarah Howell, Leon Zakrzewski, Martina Urschitz, Bernd Tschapeller, Christina Gatschelhofer, Franz Feichtner, Fiona Lawrence, Thomas R. Pieber

Diabetes Care Feb 2021, 44 (2) 448-455; DOI: 10.2337/dc20-1017
You have access
Effect of Afrezza on Glucose Dynamics During HCL Treatment
Alfonso Galderisi, Nathan Cohen, Peter Calhoun, Kristen Kraemer, Marc Breton, Stuart Weinzimer, Eda Cengiz

Diabetes Care Sep 2020, 43 (9) 2146-2152; DOI: 10.2337/dc20-0091
You have access
Prevalence of and Characteristics Associated With Overbasalization Among Patients With Type 2 Diabetes Using Basal Insulin: A Cross-Sectional Study
Kevin Cowart, Wendy H. Updike, Rashmi Pathak

Clinical Diabetes Jan 2021, cd200080; DOI: 10.2337/cd20-0080
You have access
Pharmacokinetic and Pharmacodynamic Head-to-Head Comparison of Clinical, Equivalent Doses of Insulin Glargine 300 units · mL⁻¹ and Insulin Degludec 100 units · mL⁻¹ in Type 1 Diabetes
Paola Lucidi, Paola Candeloro, Patrizia Cioli, Anna Marinelli Andreoli, Chiara Pascucci, Angela Gambelunghe, Geremia B. Bolli, Carmine G. Fanelli, Francesca Porcellati

Diabetes Care Jan 2021, 44 (1) 125-132; DOI: 10.2337/dc20-1033
Open Access
Early Observation and Mitigation of Challenges in Diabetes Management of COVID-19 Patients in Critical Care Units
Osama Hamdy, Robert A. Gabbay

Diabetes Care Aug 2020, 43 (8) e81-e82; DOI: 10.2337/dc20-0944
Open Access
A Randomized Trial Evaluating the Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec With or Without Metformin, in Adults With Type 2 Diabetes (ONSET 9)
Wendy S. Lane, Elena Favaro, Naveen Rathor, Hak C. Jang, Maiken I.S. Kjærsgaard, Alejandra Oviedo, Ludger Rose, Peter Senior, Giorgio Sesti, Alfonso Soto Gonzalez, Edward Franek

Diabetes Care Aug 2020, 43 (8) 1710-1716; DOI: 10.2337/dc19-2232
You have access
Treatment Patterns, Adherence, and Persistence Associated With Human Regular U-500 Insulin: A Real-World Evidence Study
Jieling Chen, Christi Y. Kao, Xuanyao He, Ludi Fan, Jeffrey A. Jackson, Rattan Juneja

Diabetes Spectrum Aug 2020, 33 (3) 264-272; DOI: 10.2337/ds19-0060
You have access
Connecting Rodent and Human Pharmacokinetic Models for the Design and Translation of Glucose-Responsive Insulin
Jing Fan Yang, Xun Gong, Naveed A. Bakh, Kelley Carr, Nelson F.B. Phillips, Faramarz Ismail-Beigi, Michael A. Weiss, Michael S. Strano

Diabetes Aug 2020, 69 (8) 1815-1826; DOI: 10.2337/db19-0879

Main menu

User menu

Search

Clinical Therapeutics/New Technology-Insulins

Pages

Navigate

More Information

Other ADA Resources